Placebo matching BI 765845

DRUG2 trials

Sponsors

Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG, Boehringer Ingelheim Espana S.A., Boehringer Ingelheim

Conditions

Myocardial Infarctionacute myocardial infarction

Phase 2

Randomised study for double-blind, placebo-controlled evaluation of BI 765845 on top of standard of care in patients with myocardial infarction

CompletedCTIS2022-502788-39-00

Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG, Boehringer Ingelheim Espana S.A.acute myocardial infarction

Start: 2023-11-27End: 2025-11-11Target: 194Updated: 2025-08-06

IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

TerminatedNCT06139328

Boehringer IngelheimMyocardial Infarction

Start: 2023-12-05End: 2025-12-02Updated: 2026-02-04